Roth Sees 'Significant' and 'Impressive' Cost Efficiencies in TG Therapeutics' (TGTX) CLL Combo Phase 3

Roth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Buy with a price target of $25 following recent discussions with management.

Analyst Joseph Pantginis said TGTX comments indicate significant and impressive cost efficiencies for the upcoming Phase III combination study (under SPA) with TG-1101 and Imbruvica in CLL patients.

Pantginis elaborated, We believe the projected cost for the Phase III study is impressive and believe that TG should have no problems enrolling the study on a timely basis. With patients on both arms slated to receive Imbruvica, we believe this is a compelling hook to enroll as well as the focused and premium physician care patients will receive during the course of the study. We believe TG continues to solidify its place in oncology with what we believe to be differentiated "hot target" drug candidates in TG-1101 and TGR-1202. We also look forward to the disclosure of additional Phase III studies by year end. We believe that TGTX is in control of whether the company wants to partner its products or not. It has already shown the ability to form fruitful alliances such as with Pharmacyclics' (Nasdaq: PCYC) Imbruvica and the ongoing combo study with TG-1101. Management has commented previously that the company would like to hold onto the drugs for as long as possible, and possibly not partner at all. However, given the favorable terms that Infinity (Nasdaq: INFI) secured in the deal with AbbVie (NYSE: ABBV) for its PI3K inhibitor and given TGTX's clinical data to date, we believe TGTX would have significant leverage if it chose to pursue a partnership.

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.

TG Therapeutics closed at $9.93 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Acrivon Therapeutics Inc (ACRV) PT Raised to $30 at Piper Sandler
• Premier Financial Corp. (PFC) PT Raised to $22 at Piper Sandler